Breast cancer remains the most frequently diagnosed cancer, which is the leading cause of cancer-related mortality in women worldwide. Incidence rates vary across countries, with higher rates observed in regions with higher human development indices. Genetic mutations, particularly in BRCA1 and BRCA2 genes, play a significant role in breast cancer susceptibility, with implications for risk assessment and treatment decisions. Treatment options include surgery, chemotherapy and targeted therapies such as PARP inhibitors, with ongoing research focusing on improving outcomes and addressing drug resistance. Increased awareness, early detection and advancements in treatment have contributed to improvements in breast cancer outcomes in developed regions. However, disparities in access to healthcare and resources persist, particularly in low and middle income countries. Addressing these disparities through organized screening programs, improved access to quality healthcare and continued research into personalized treatment approaches is crucial to reduce the global burden of breast cancer and improving outcomes for all patients. The review aims to provide a comprehensive overview of the epidemiology, risk factors, genetic mutations and treatment options associated with breast cancer, highlighting the global burden of the disease and its implications for public health.
Zainulabidin et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: